ABSTRACT Complete follow-up data were obtained from 229 consecutive patients who underwent percutaneous transluminal coronary angioplasty (PTCA) between 1979 and 1982 (mean follow-up 14 months, range 6 to 37). Single-vessel disease was present in 143 and multivessel disease in 86. PTCA was successful in 153 patients (67%). Failure was followed initially by bypass surgery in 59 and by continued medical therapy in 17. After successful PTCA, 90% of patients were improved subjectively and 74% were asymptomatic at follow-up. After unsuccessful PTCA but prompt bypass, 90% were improved subjectively and 85% were asymptomatic. Among the 229 patients, 39 (17%) required an additional intervention because of angina during follow-up; 15 of these had repeat PTCA and 18 had bypass surgery. Among patients with successful PTCA, revascularization was complete in 77% and partial in 23%. The completeness of revascularization with PTCA had a significant impact on followup. The follow-up data of patients with successful single-vessel PTCA and of those with multivessel disease with complete revascularization were similar. When the patients with complete revascularization were compared with those with multivessel disease but incomplete revascularization, the followup data were characterized by a higher incidence of angina or need for bypass surgery in the latter group (63%) than in the former group (29%); those with incomplete revascularization also had a significantly reduced event-free survival. Circulation 71, No. 4, 754-760, 1985. 
PERCUTANEOUS TRANSLUMINAL coronary angioplasty (PTCA) has rapidly become an established therapeutic option for selected patients with coronary artery disease. '-" It is of proven efficacy both for the relief of symptoms and for the improvement of myocardial function.5 7 8.12 Despite growing acceptance, several problems remain, including the need to document its long-term efficacy. Although the National Heart, Lung, and Blood Institute (NHLBI) PTCA Registry provides information on the follow-up of patients who have undergone PTCA, it does not provide follow-up data on the outcome of patients with singlevessel disease compared with those with multivessel disease or address the question of completeness of revascularization. " ' A complete follow-up of all patients who undergo PTCA at the Mayo Clinic has been maintained. The purpose of this report is to document the continuing follow-up results among these patients, particularly with respect to the need for subsequent intervention, the effect of complete and incomplete revascularization, and the incidence of subsequent cardiovascular events.
Materials and methods
Patients and selection criteria. From September 1979 to December 1982, 244 patients underwent PTCA at the Mayo Clinic. Fifteen of these patients received streptokinase before or during PTCA, and they were excluded from analysis. The remaining 229 patients formed the basis of this study. All patients had at least 6 months of follow-up, a minimum selected because most restenosis occurs within this time. 13 The criteria for patient selection were (1) symptomatic myocardial ischemia poorly responsive to medical treatment in patients who were candidates for coronary artery surgery and (2) coronary anatomy suitable for dilatation. Stenosis of 70% or greater diameter reduction in the proximal, middle, and distal right coronary artery, in the proximal and middle left anterior descending and first diagonal coronary arteries, or in the proximal and distal circumflex and first and second obtuse marginal coronary arteries (Coronary Artery Surgery Study tCASSI seg-CIRCULATION ments 1, 2, 3, 12, 13, 15, 18, 19, 20 , and 21'4) was considered suitable for PTCA if the segment supplied an area of viable myocardium. The severity of stenosis was assessed in multiple angiographic views and then averaged.
Procedural details. PTCA was performed as previously described,2 with cardiovascular surgical standby. All patients gave written informed consent. Steerable balloon catheter systems were not used routinely during this time. In patients with multivessel disease, PTCA was attempted first at the site considered to be the primary cause of the symptoms. This determination was based on the correlation between ischemic electrocardiographic changes, regional left ventricular function, and the lesions found at angiography.
If dilatation of the most severe stenosis was unsuccessful, PICA of the other lesions was not attempted. Patients in whom dilatation was unsuccessful usually underwent coronary artery bypass graft surgery (CABG) within 48 hr after the attempt at PTCA.
Definitions (1 Success of PTCA. PTCA was successful in 153 patients, and in that group it reduced the mean stenosis from 91% to 26%. The success rate was 67% among the series as a whole, 61% among patients with singlevessel disease, and 77% among those with multivessel disease. The successful and unsuccessful groups did not differ significantly with respect to age, sex, mean duration of angina, incidence of unstable angina, or history of prior infarction (table 1) .
Of the 76 patients in whom PTCA was unsuccessful, 59 (78%) underwent CABG (U-Surg) and 17 (22%) continued on medical therapy (U-Med).
Completeness of revascularization. Among the 153 patients in whom PTCA was successful, revascularization was complete in 118 (77%). These 118 included the 87 patients with single-vessel disease in whom PTCA was successful and 31 of the 66 patients with multivessel disease in whom PTCA was successful. In the other 35 patients with multivessel disease and successful PTCA, revascularization was only partial.
Complications of PTCA. The major complication was significant luminal compromise in the dilated segment by major dissection or coronary thrombus. This occurred in 27 patients (12%). Follow-up. The 228 hospital survivors were followed up for a mean of 14 months (range 6 to 37) (figure 1). The median follow-up was 11 months. There were no deaths. Myocardial infarction occurred in seven patients (3%), of whom five were in the successful PTCA group, one in the U-Surg group and one in the U-Med group. Of the patients in the successful PTCA group and U-Surg group, 90% were improved subjectively at the latest follow-up. Of the patients in the U-Med group, 88% were improved subjectively but 35% had required repeat intervention, either a repeat attempt at PTCA or CABG during the follow-up.
Functional status and influence of revascularization. Figure 2 shows the distributions of patients among the functional classes: the entire series before PTCA and the several outcome groups at follow-up. Before attempted PTCA, 83% of the patients had been in Canadian Heart class III or IV. After successful PTCA, 9% were in class ILL or IV and 74% were asymptomatic; after unsuccessful PTCA followed by CABG surgery, 7% were in class III or IV and 85% were asymptomatic. Of the 17 patients who initially continued with medical therapy after unsuccessful PTCA, only three (18%) remained in class III follow-up and without need of CABG, but of those with multivessel disease and only partial revascularization, just 37% were free of angina and had not required CABG. (Revascularization achieved in patients with single-vessel disease was considered complete, by definition.) Event-free survival (and extent of revascularization). In assessment of event-free survival, the events accepted as end points were angina pectoris, repeat PTCA, CABG, myocardial infarction, and cardiac death. Patients were excluded from further analysis after occurrence of their first event. At 12 months, event-free survival had been achieved by 61% of patients with successful PTCA and by 78% of those with unsuccessful PTCA and prompt CABG (figure 3). Given the absence of cardiac death during follow-up and the low 13 (37) 4 (13) 11 (13) Unless specified, data are number of patients, with percentages in parentheses. Months after PTCA FIGURE 3. Event-free survival after unsuccessful PTCA followed by CABG (n = 58) and after successful dilatation of at least one vessel (n = 153).
(3%) infarction rate, this difference is due almost entirely to the development of angina and need for repeat PTCA or CABG in the group of patients with initially successful PTCA. The rate of event-free survival was significantly higher after complete revascularization than after partial revascularization (figure 4). At 6 months, 79% of patients with complete revascularization achieved event-free survival but only 43% of those with incomplete revascularization achieved event-free survival (figure 4). Discussion PTCA has already achieved a major role in the treatment for coronary artery disease. Its safety and early efficacy in subsets of patients with coronary artery disease, particularly those with single-vessel disease, have been well documented. 1-l l Questions remain about its long-term efficacy, the need for repeat procedures, criteria for patient selection (including those with multivessel disease), and its comparability with the proven efficacy of CABG. In the absence of a prospective randomized trial, valuable information can be obtained by careful analysis of complete follow-up results in early cohorts of patients who have undergone PTCA.
Effilcacy of treatment. In the series reported here, patients had at least 6 months of follow-up (median 11 months). The 6 month minimum was chosen because restenosis after PTCA usually occurs within this interval . 1 3
The results are encouraging in terms of relief of angina, absence of late mortality, and low incidence of subsequent infarction. After successful PTCA, 90% of patients reported improvement in clinical status and 74% remained free of angina. Only 22% required a subsequent procedure for recurrence of angina in a mean follow-up of 14 months, and repeat PTCA alone was effective for approximately half of them.
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In patients with unsuccessful initial PTCA who promptly underwent CABG (U-Surg), again 90% were improved subjectively at follow-up and 85% remained free of angina. Moreover, this success was achieved without repeat PTCA or CABG during the follow-up. In contrast, patients with unsuccessful PTCA who did not undergo initial surgery (U-Med) have had a higher incidence of angina and requirement for subsequent intervention. These data suggest that (1) the benefits of CABG are not compromised by a prior PTCA attempt and (2) multivessel disease and desirability of complete revascularization. In studies of surgical bypass, the relationship between completeness of revascularization and relief of angina has been emphasized.">2-If PTCA is to be applied in patients with multivessel disease, its effectiveness in achieving complete revascularization should be similarly examined. The revascularization strategy may differ with the two procedures. At surgery, stenoses of 50% to 70% reduction would be bypassed if there were stenoses greater than 70% in other major cardiac coronary vessels. This policy is dictated by the desire to effect complete revascularization at one operation in the hope of obviating subsequent procedures, with attendant higher risks and less satisfactory results. These considerations may be less important in the application of the less invasive, aggressive approach. Our practice, therefore, has been to dilate stenoses of 70% or greater diameter reduction and not to interfere with less severe lesions. This method is justified by the fact that complications of PTCA occur with the same frequency in patients with mild stenoses as in those with severe stenoses and that restenosis, if it occurs, may become more severe than the original lesion.22 Therefore, although stenosis of 50% to 70% reduction may contribute toward the categorization of a case as multivessel disease, we have not included such lesions in the definition of complete or incomplete revascularization after PTCA.
The extent of revascularization has a significant implication for PTCA. This is of particular importance in patients with multivessel disease, in whom one lesion may be successfully dilated but other significant lesions may remain unchanged. The follow-up data of patients with successful PTCA for multivessel disease were similar to those of patients with PTCA for singlevessel disease only when all significant proximal lesions were dilated. The event-free survival in these groups was similar to that of patients with unsuccessful dilatation followed by CABG.
The outcome of PTCA in patients with single-vessel disease or multivessel disease with complete revascularization was in marked contrast to patients with multivessel disease with incomplete revascularization. Of the patients with multivessel disease and incomplete revascularization by PTCA, 63% had angina or had required surgery at follow-up. This is in contrast with the group of patients with multivessel disease and complete revascularization or single-vessel disease and complete revascularization, in whom only 29% had angina or CABG at follow-up. After complete revascularization, 72% of patients achieved 12 months of event-free survival, but after incomplete revascularization, only 40% of patients had 7 months of event-free survival. Of patients with multivessel disease and incomplete revascularization, 23% required subsequent CABG, but of patients with multivessel disease and complete revascularization, only 13% required CABG.
Although the numbers were small, if complete revascularization is achieved in patients with multivessel disease (or in those with single-vessel disease), recurrence of angina usually seems to be associated with restenosis. This result contrasts with the experience after incomplete revascularization in patients with multivessel disease, in which recurrent angina often is caused by progression of underlying disease or residual stenoses.
Conclusion. Successful PTCA offers an excellent chance of continued relief of symptoms over time. Restenosis remains a problem, but if it occurs, a second PTCA may be performed effectively and safely. In patients with multivessel disease, the completeness of revascularization seems to be important. In these patients, PTCA should be used with the full knowledge that incomplete revascularization seems to be associated with a higher incidence of recurrent angina than complete revascularization.
